The Howard Hughes Medical Institute said this week that it has selected Cold Spring Harbor Laboratory researchers Gregory Hannon and Scott Lowe, Massachusetts Institute of Technology's David Bartel, Rockefeller University's Thomas Tuschl, and Columbia University's Oliver Hobert as new HHMI investigators.
The institute chose 43 scientists for the honor through a nationwide competition that began last year when it asked approximately 200 universities, medical schools, and institutes to nominate candidates who demonstrated exceptional promise within four to 10 years of their becoming independent scientists, according to HHMI. More than 300 individuals were nominated.
Sirna Therapeutics said this week that it has named Keith Yamamoto as chairman of the company's scientific advisory board.
According to Sirna, Yamamoto is currently executive vice dean at the University of California, San Francisco School of Medicine. Sirna recently announced that it was relocating its corporate headquarters to San Francisco (see RNAi News, 3/11/2005).
Archemix said this week that it has named Frank Douglas to its board of directors.
Douglas, who is retired, previosuly served as executive vice president of drug innovation and approval, as well as CSO, of Aventis Pharma. He is currently executive-in-residence at the Massachusetts Institute of Technology's Sloan School of Management.